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The prevalence of non-communicable diseases (NCDs), especially diabetes mellitus (DM), is increasing globally. Screening for DM in pregnancy is undertaken after 16–24 
weeks. Pre-pregnancy and early first trimester screening are not 
routinely done in most of the developing countries; therefore, 
some mothers with pre-pregnancy DM (PPDM) may get labeled as 
gestational DM (GDM). This may lead to a missed opportunity of 
maintaining euglycemia during the early period of organogenesis, 
resulting in diabetic embryopathy and congenital anomalies [1,2]. 
Even though large-for-gestational-age (LGA) babies are expected, 
many small-for-gestational-age (SGA) babies are born to mothers 
with DM. It is known that neonatal outcome varies with respect 
to PPDM and GDM [3], in comparison to mothers without DM. 
Hence, we performed a study to compare the neonatal parameters 
such as SGA, LGA, and outcome among babies born to mothers 
with PPDM, GDM, and no DM.
MATERIALS AND METHODS
This cohort study was conducted in a government tertiary care 
teaching hospital during 1-year period. Research Committee and 
Institutional Ethics Committee approval and informed consent 
from the participants were obtained before the study. All prenatal 
mothers were enrolled before 6 weeks of gestation, and exclusion 
criteria were known medical conditions such as hypertension and 
systemic diseases. Sample size was calculated as 453 assuming a 
17% prevalence of DM among prenatal mothers. A cohort of 480 
mothers was followed until delivery. A total of 70 mothers, with 
DM before pregnancy, and 23 mothers, who had HbA1C >6.5% 
in early first trimester, confirmed as per the American Diabetes 
Association, 2011 criteria [4], formed the PPDM subgroup. Of 
480 mothers, 187 mothers, who were negatively screened at 
enrolment and later confirmed as GDM by one-step-75 g OGTT 
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as per IADPSG, 2010 criteria [5] at 24–28 or 32–34 weeks’ 
gestation, formed the GDM group. The rest of the 200 mothers, 
who remained screen negative throughout pregnancy, formed the 
non-DM group.
All mothers with DM were initiated on dietary therapy as per 
the ADA, 2008 criteria [6], Metformin and insulin were added 
as per the ADA, 2011 guidelines [4]. Maternal medications and 
glycemic control were recorded. Mean glucose levels, fasting 
<110, and 2 h post-prandial <140 mg/dl were considered as 
optimum control, as per Diabetes in Pregnancy Study group of 
India, 2013 [7]. Plasma glucose was measured by enzymatic 
hexokinase method (Cobas 6000, Roche Diagnostics) and 
hemoglobin A1c by high-performance liquid chromatography 
method in a NABL Accredited Lab, attached to the institution.
Neonatal parameters such as birth weight, gestational 
age, multiple pregnancy, congenital anomalies, metabolic 
derangements, indication and duration of neonatal intensive care 
unit (NICU) care, and mortality were recorded and compared. 
Neonatal diagnosis and management, including criteria for NICU 
admission, were based on the national neonatology forum (NNF), 
India, 2011 guidelines [8]. Data were analyzed using SPSS 
version 16.0 for Windows. Descriptive statistics was used for 
participant characteristics and Fisher’s exact/Chi-square tests for 
proportions.
RESULTS
Of total 480 pregnancies, there were 481 babies. There were three 
neonatal mortalities, two in PPDM and one each in the other 
two subgroups and one intrauterine death in GDM subgroup. 
The age of mothers ranged from 19 to 37 years, and the mean 
age was comparable in three subgroups (P > 0.05). Majority of 
them belonged to middle or low socioeconomic status. Maternal 
overweight and obesity were more in PPDM and GDM subgroups. 
The PPDM group consisted of 93 mothers and 94 babies, 
including a pair of twins (19.5%). A total of 187 mothers and 
187 babies (one pair of twins, excluding one intrauterine death) 
formed the GDM group (39%) and 200 mothers and their babies 
formed non-DM group (41.5%). The baseline characteristics in 
the various subgroups are summarized in Table 1.
Those detected at early first trimester screen before 6 weeks 
were grouped on PPDM, in view of hyperglycemia, starting 
at least 3 months before diagnosis (5.6%), and those detected 
at second and third trimester screens were grouped as GDM 
(17.5%). 76 mothers (81.7%) with PPDM and 118 (63.1%) 
with GDM were on insulin, whereas 60 (64.52%) in PPDM and 
127 (67.91%) in GDM group had optimum glycemic control. 
Cesarean section rate was 42.55%, 36.9%, and 34%, and NICU 
admission rates were 90.42%, 62.03%, and 22%, respectively, in 
PPDM, GDM, and non-DM subgroups.
Neonatal parameters and outcome showed significant 
differences in the three subgroups (Table 2). Differential outcome 
was noted with respect to birth weight, gestational age, NICU 
admission and duration of stay, hypoglycemia, hypocalcemia, 
and meconium-stained amniotic fluid, birth trauma, and shoulder 
dystocia. Hyperbilirubinemia and sepsis were comparable in all 
three subgroups. Adverse outcome and morbidity were more in 
those with DM compared to non-DM. Appropriate-for-gestational-
age (AGA) babies were 34.04%, 63.1%, and 78%, respectively, in 
PPDM, GDM, and non-DM subgroups. AGA babies were more 
in those with optimum glycemic control. SGA babies were more 
in PPDM group (54%), followed by GDM (26%) and non-DM 
group (21%) while LGA babies were less, i.e., 9.6%, 5.9%, and 
0.5%, respectively, in these three subgroups.
The following observations were statistically significant 
among PPDM compared to GDM: SGA (relative risk [RR] 2.1, 
95% confidence interval [CI] 2.9–3.6), congenital anomalies 
(RR 3.3, 95% CI 5.1–8.8), and neonatal mortality (RR 4, 95% CI 
2.1–3.2). The duration of NICU stay was more in PPDM (16±0.6 
days compared to 8±0.5 days in GDM and 1±0.5 days in non-DM 
group). Prematurity (p<0.05) and NICU admission, with longer 
stay, were also more in PPDM subgroup. Macrosomia (birth 
weight >4.5 kg) in term babies and birth trauma such as brachial 
plexopathy and fracture clavicle were more in GDM subgroup 
(p<0.05). Hypoglycemia, NICU admission with longer stay, 
and macrosomia were more in those with poor glycemic control 
(p<0.05).
Among those with congenital anomalies, cardiac defects 
such as shunt lesions, transposition of great arteries (d-TGA), 
Tetralogy of Fallot (TOF), and asymmetric septal hypertrophy 
Table 1: Baseline characteristics and sociodemographic profile in the various subgroups 
Parameter PPDM n (%) GDM n (%) Total DM n (%) Non-DM n (%) Total pooled n (%)
Number of mothers 93 (100) 187 (100) 280 (100) 200 (100) 480 (100)
Number of babies 94 (100) 187 (100) 281 (100) 200 (100) 481 (100)
Middle and low socioeconomic status 88 (94.62) 167 (89.30) 255 (91.07) 182 (91) 437 (91.04)
Maternal overweight BMI>23 Kg/m2 10 (10.75) 28 (14.98) 38 (13.57)  27 (13.5) 65 (13.51)
Maternal obesity BMI>27 Kg/m2 8 (8.6) 18 (9.60)* 26 (9.3)* 10 (5.0) 28 (5.83)
Pregnancy-induced hypertension 14 (15.05) 37 (19.79) 51 (18.21) 36 (18) 87 (18.12)
Mothers with DM 93 (100) 187 (100) 280 (100) NA 280 (100)
Mothers on insulin therapy 76 (81.7) 118 (63.10) 194 (69.29) NA 194 (69.29)
Mothers with optimum glycemic control 60 (64.52) 127 (67.91) 187 66.55) NA 187 (66.55)
Mothers with suboptimum glycemic control 33 (35.48) 60 (32.09) 93 (33.21) NA 93 (33.21)
*Significant P<0.05. PPDM: Pre-pregnancy diabetes mellitus, GDM: Gestational diabetes mellitus, Total DM: Total diabetes mellitus, Non-DM: Non-diabetes mellitus
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(ASH) were noted in two-third of babies and non-cardiac defects 
such as anorectal malformation and ectrodactyly in the rest. There 
was one baby with Down syndrome, AV canal defect, and anal 
atresia in PPDM subgroup.
DISCUSSION
In the present study, the proportion of mothers with DM detected 
at the early first trimester screen before 6 weeks of gestation was 
5.6%. They were included as PPDM, due to raised HbA1C in the 
past 3–4 months, which comprised of pre-pregnancy and early 
pregnancy period. This is of great concern as screening for GDM 
is routinely done around 20 weeks or later, as pregnancy-related 
hyperglycemia is rare before this period. However, this can lead 
to a missed opportunity of ensuring glycemic control, at least 
in some mothers, during the phase of organogenesis. This can 
result in embryopathy, congenital anomalies, and SGA babies. 
Hence, HbA1C screen, followed by a one-step 75 g OGTT, is 
recommended [9] at registration, starting from early first trimester 
or pre-pregnancy visit. The use of HbA1c is highlighted, in view 
of the previous report of the inadequacy of plasma glucose in the 
diagnosis of DM, especially in Asian women [10]. This approach 
is relevant due to the current epidemic proportions of DM and 
NCDs among the general population. The proportion of mothers 
with GDM has been reported to be 2.4–24% [11,12] and 17% in 
one study from the same region [13], comparable to 17.5%, noted 
in the present study.
In this study, glycemic control was estimated as follows: 
Mean glucose levels - fasting <110 mg/dl and 2 h post-prandial 
<140 mg/dl [7], as per the 2011 guidelines; as against the latest revised 
criteria of fasting glucose <95 and 2 h post-prandial <120 mg/dl, that 
came in after the initiation of the study in 2017 [14]. The majority 
in PPDM and GDM were on insulin, and more than two-third had 
optimum glycemic control. Achieving glycemic control during 
pregnancy is essential for better feto-maternal outcome [15]. 
Medical and nutritional care in DM complicating pregnancy has 
been reviewed and standardized by different working groups [15,16]. 
Cesarean section rate of around 40% noted in the present study 
among mothers with DM was comparable with non-DM subgroup 
and the recent Auckland study [17]. Some previous studies have 
reported higher CS rates up to 74% [18].
Neonatal complications were more in PPDM and GDM 
subgroups and outcome varied with respect to the onset of DM 
and glycemic control. Neonatal anthropometric measurements 
showed a changing profile compared to other studies with respect 
to LGA and SGA babies [19,20]. This may be attributable to 
the differences in dietary pattern, lesser weight gain during 
pregnancy, and low pre-pregnancy BMI among the participants. 
High LGA and macrosomia rate up to 28% have been reported 
from a North India in 2011 [21]. Insulin therapy is reported to 
reduce macrosomia [22]. Optimum control resulted in more AGA 
babies in the present study. Hypoglycemia, NICU admission 
with longer stay, and macrosomia were more in those with poor 
glycemic control. The proportion of macrosomia and birth trauma 
was significantly more in GDM subgroup. The proportion of 
SGA babies was as high as 54% in PPDM subgroup, as against 
24%, reported from the North Indian study [21]. This may be 
attributable to diabetic embryopathy and restrictive dietary intake 
Table 2: Clinical profile and neonatal outcome in the various subgroups: PPDM, GDM, total DM, non-DM, and total pooled subgroups
Neonatal parameter/outcome PPDM n (%) GDM n (%) Total DM n (%) No,-DM n (%) Total pooled n (%)
Number of babies 94 (100) 187 (100) 281 (100) 200 100) 481 (100)
Neonatal mortality 2 (2.13)* 1 (0.53) 3 (1.07) 1 (0.5) 4 (0.83)
NICU admission 85 (90.42)* 116 (62.03)* 201 (71.53)* 44 (22.0) 245 (50.93)
Macrosomia 2 (2.13)* 9 (4.82)* 11 (3.91)* 0 (0) 11 (2.29)
LGA babies 9 (9.57)* 11 (5.88)* 20 (7.12)* 2 (0.5) 22 (4.57)
SGA babies 51 (54.26)* 49 (26.20) 100 (35.59)* 42 (21) 142 (29.52)
AGA babies 32 (34.04) 118 (63.1) 150 (53.35) 156 (78) 306 (63.62)
Prematurity 40 (42.55)* 65 (34.79)* 105 (37.37)* 28 (14) 133 (27.65)
Respiratory distress 34 (45.74)* 56 (29.95)* 90 (32.02)* 26 (13) 116 (24.12)
Congenital anomalies 9 (9.57)* 5 (2.67) 14 (4.98)* 2 (1.0) 16 (3.33)
MSAF 12 (12.77)* 17 (9.09)* 29 (10.32)* 11 (5.5) 40 (8.31)
Birth asphyxia 2 (2.12) 8 (4.28) 10 (3.56) 6 (3.0) 16 (3.33)
Hypoglycemia 15 (15.96)* 24 (12.83)* 39 (13.88)* 12 (6) 51 (10.60)
Hypocalcemia 2 (2.12) 4 (2.13) 6 (2.14) 2 (1.0) 8 (1.66)
Hypomagnesemia 1 (1.07) 1 (0.53) 2 (0.71) 0 (0) 2 (0.42)
Hyperbilirubinemia 9 (9.57) 22 (11.74) 31 (11.02) 26 (13) 57 (11.85)
Sepsis 2 (2.12) 4 (2.13) 6 (2.14) 3 (1.5) 9 (1.87)
Birth trauma 1 (1.07) 5 (2.67) 6 (2.14) 1 (0.5) 7 (1.46)
Shoulder dystocia 2 (2.12) 4 (2.13) 6 (2.14) 1 (0.5) 7 (1.46)
Caesarian section 40 (42.55) 69 (36.90) 109 (38.79) 68 (34) 177 (36.8)
*Significant P<0.05. PPDM: Pre-pregnancy diabetes mellitus, GDM: Gestational diabetes mellitus, Total DM: Total diabetes mellitus, No,-DM: No,-diabetes mellitus, 
SGA: Small-for-gestational-age, LGA: Large-for gestational-age
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among the participants. Intrauterine growth retardation resulting 
in SGA babies has a poor immediate outcome and early onset of 
adulthood diseases such as DM, as per Barker hypothesis [23]. 
LGA and macrosomia result in more immediate complications 
and future obesity.
NICU admission with longer stay, SGA, prematurity, and 
congenital anomalies were more in PPDM subgroup. These 
findings are in accordance with other reported studies [18,24]. 
The proportion of prematurity was 3-fold more in PPDM than 
non-DM, which was on par with the Auckland study [17]. The 
proportion of prematurity is liable to vary as per the decision 
for elective deliveries and CS. Respiratory distress was noted in 
nearly half in PPDM and GDM, in comparison to 10% reported 
from the North Indian study [21]. Macrosomia and birth trauma 
such as brachial plexopathy and fracture clavicle were more in the 
GDM group [21,25]. The proportion of congenital anomalies was 
around 10%, on par with the North Indian study [21].
Among congenital anomalies, cardiac defects were noted 
in two-third; shunt lesions, d-TGA, TOF and asymmetric 
septal hypertrohy (ASH). ASH is a forerunner of hypertrophic 
obstructive cardiomyopathy (HOCM). HOCM is reported as one 
of the causes of unexplained sudden mortality in these babies. A 
5-fold increase in cardiac defects has been reported in mothers with 
DM [26]. The non-cardiac defects were anorectal malformation 
and ectrodactyly. Caudal regression syndrome, which is a known 
anomaly [27], was not noted in the present study. Mortality, in the 
present study, was low compared to other previous studies [28,29], 
which is attributable to the protocol based on neonatal care [8]. 
The clinical profile and neonatal outcome were different in 
PPDM and GDM, compared to non-DM subgroup, as observed in 
other studies [28,30]. This warrants early pre-pregnancy or first 
trimester screening and optimum glycemic control throughout 
pregnancy. The limitations of the study were small sample size, 
unequal distribution of mothers in the three subgroups, and non-
uniform glycemic control in those with PPDM and GDM.
CONCLUSION
A change in profile with more SGA and less LGA babies was 
noted. This is of public health importance, in view of short-term as 
well as long-term and transgenerational outcome, including early 
onset of DM in the offspring. A differential neonatal outcome 
was noted with respect to the onset of DM and glycemic control, 
among mothers. Hence, pre-pregnancy/early first trimester screen 
with HbA1C, followed by one-step-75 mg OGTT, along with 
second and third trimester screen and optimum glycemic control, 
throughout pregnancy, is recommended.
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